GB0616747D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB0616747D0
GB0616747D0 GB0616747A GB0616747A GB0616747D0 GB 0616747 D0 GB0616747 D0 GB 0616747D0 GB 0616747 A GB0616747 A GB 0616747A GB 0616747 A GB0616747 A GB 0616747A GB 0616747 D0 GB0616747 D0 GB 0616747D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0616747A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GB0616747A priority Critical patent/GB0616747D0/en
Publication of GB0616747D0 publication Critical patent/GB0616747D0/en
Priority to US12/160,752 priority patent/US20110034454A1/en
Priority to KR1020087018260A priority patent/KR20080083188A/en
Priority to PCT/GB2007/000037 priority patent/WO2007080382A1/en
Priority to JP2008549922A priority patent/JP2009523161A/en
Priority to BRPI0706395-4A priority patent/BRPI0706395A2/en
Priority to AU2007204208A priority patent/AU2007204208A1/en
Priority to CA002635997A priority patent/CA2635997A1/en
Priority to EP07700340A priority patent/EP1979325A1/en
Priority to CA002660758A priority patent/CA2660758A1/en
Priority to RU2009110255/04A priority patent/RU2440349C2/en
Priority to TW96130916A priority patent/TW200817384A/en
Priority to MX2009002046A priority patent/MX2009002046A/en
Priority to ES07789273T priority patent/ES2393215T3/en
Priority to PCT/GB2007/003173 priority patent/WO2008023159A1/en
Priority to EP07789273A priority patent/EP2057140B1/en
Priority to JP2009525103A priority patent/JP5534811B2/en
Priority to AU2007287428A priority patent/AU2007287428B2/en
Priority to BRPI0715609-0A2A priority patent/BRPI0715609A2/en
Priority to KR1020097005961A priority patent/KR101435231B1/en
Priority to CN200780039262.7A priority patent/CN101541781B/en
Priority to US12/438,477 priority patent/US20090325957A1/en
Priority to CNA2007800392665A priority patent/CN101558046A/en
Priority to CL200702446A priority patent/CL2007002446A1/en
Priority to EP07789303A priority patent/EP2057129A1/en
Priority to PCT/GB2007/003211 priority patent/WO2008023180A1/en
Priority to JP2009525108A priority patent/JP2010501537A/en
Priority to UY30559A priority patent/UY30559A1/en
Priority to US11/844,092 priority patent/US7750003B2/en
Priority to PE2007001151A priority patent/PE20081362A1/en
Priority to ARP070103775A priority patent/AR062526A1/en
Priority to IL192281A priority patent/IL192281A0/en
Priority to NO20082730A priority patent/NO20082730L/en
Priority to NO20090631A priority patent/NO20090631L/en
Priority to IL196998A priority patent/IL196998A0/en
Priority to ZA200901015A priority patent/ZA200901015B/en
Priority to CO09017337A priority patent/CO6150160A2/en
Priority to HK09108580.0A priority patent/HK1130776A1/en
Ceased legal-status Critical Current

Links

GB0616747A 2006-01-11 2006-08-24 Novel compounds Ceased GB0616747D0 (en)

Priority Applications (38)

Application Number Priority Date Filing Date Title
GB0616747A GB0616747D0 (en) 2006-08-24 2006-08-24 Novel compounds
US12/160,752 US20110034454A1 (en) 2006-01-11 2007-01-08 Morpholino pyrimidine derivatives and their use in therapy
KR1020087018260A KR20080083188A (en) 2006-01-11 2007-01-08 Morpholino pyrimidine derivatives and their use in therapy
PCT/GB2007/000037 WO2007080382A1 (en) 2006-01-11 2007-01-08 Morpholino pyrimidine derivatives and their use in therapy
JP2008549922A JP2009523161A (en) 2006-01-11 2007-01-08 Morpholinopyrimidine derivatives and their use in therapy
BRPI0706395-4A BRPI0706395A2 (en) 2006-01-11 2007-01-08 compound, use thereof, methods for producing an antiproliferative effect in a warm-blooded animal and for treating disease, pharmaceutical composition, and process for preparing a compound
AU2007204208A AU2007204208A1 (en) 2006-01-11 2007-01-08 Morpholino pyrimidine derivatives and their use in therapy
CA002635997A CA2635997A1 (en) 2006-01-11 2007-01-08 Morpholino pyrimidine derivatives and their use in therapy
EP07700340A EP1979325A1 (en) 2006-01-11 2007-01-08 Morpholino pyrimidine derivatives and their use in therapy
CN200780039262.7A CN101541781B (en) 2006-08-24 2007-08-21 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
BRPI0715609-0A2A BRPI0715609A2 (en) 2006-08-24 2007-08-21 COMPOUND, USE OF A COMPOUND, METHODS TO PRODUCE AN ANTIPROLIFERATIVE EFFECT ON A HOT BLOOD ANIMAL, AND TO TREAT DISEASE IN A HOT BLOOD ANIMAL, AND PHARMACEUTICAL COMPOSITION
RU2009110255/04A RU2440349C2 (en) 2006-08-24 2007-08-21 Morpholinopyrimidine derivatives useful for treating proliferative disorders
TW96130916A TW200817384A (en) 2006-08-24 2007-08-21 Compounds-943
MX2009002046A MX2009002046A (en) 2006-08-24 2007-08-21 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders.
ES07789273T ES2393215T3 (en) 2006-08-24 2007-08-21 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
PCT/GB2007/003173 WO2008023159A1 (en) 2006-08-24 2007-08-21 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
EP07789273A EP2057140B1 (en) 2006-08-24 2007-08-21 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
JP2009525103A JP5534811B2 (en) 2006-08-24 2007-08-21 Morpholinopyrimidine derivatives useful for the treatment of proliferative diseases
AU2007287428A AU2007287428B2 (en) 2006-08-24 2007-08-21 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
CA002660758A CA2660758A1 (en) 2006-08-24 2007-08-21 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
KR1020097005961A KR101435231B1 (en) 2006-08-24 2007-08-21 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
CNA2007800392665A CN101558046A (en) 2006-08-24 2007-08-22 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
EP07789303A EP2057129A1 (en) 2006-08-24 2007-08-22 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
JP2009525108A JP2010501537A (en) 2006-08-24 2007-08-22 Morpholinopyrimidine derivatives useful for the treatment of proliferative disorders
CL200702446A CL2007002446A1 (en) 2006-08-24 2007-08-22 COMPOUNDS DERIVED FROM MORFOLINO PIRIMIDINA; PHARMACEUTICAL COMPOSITION; AND ITS USE TO PREPARE A MEDICINAL PRODUCT TO PRODUCE AN ANTIPROLIFERING EFFECT.
US12/438,477 US20090325957A1 (en) 2006-08-24 2007-08-22 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
PCT/GB2007/003211 WO2008023180A1 (en) 2006-08-24 2007-08-22 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
UY30559A UY30559A1 (en) 2006-08-24 2007-08-23 DERIVATIVES OF MORFOLINO PIRIMIDINA, PREPARATION PROCESSES, COMPOSITIONS CONTAINING THEM AND APPLICATIONS
US11/844,092 US7750003B2 (en) 2006-08-24 2007-08-23 Compounds-943
PE2007001151A PE20081362A1 (en) 2006-08-24 2007-08-24 MORPHOLINO PYRIMIDINE DERIVATIVES AS INHIBITORS OF mTOR KINASE AND PI3K
ARP070103775A AR062526A1 (en) 2006-08-24 2007-08-24 DERIVATIVES OF 4- (3-METHYLMORFOLIN-4-IL) PYRIMIDINE AND MORFOLIN-4-IL-PYRIMIDINE AS INHIBITORS OF MTOR QUINASA AND PI3K, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND THE USE OF THEM IN THE MANUFACTURE OF DRUGS FOR MEDICATION OF DIFFERENT TYPES OF CANCER.
IL192281A IL192281A0 (en) 2006-01-11 2008-06-18 Morpholino pyrimidine derivatives and their use in therapy
NO20082730A NO20082730L (en) 2006-01-11 2008-06-19 Morpholinopyrimidine derivatives and their use in therapy
NO20090631A NO20090631L (en) 2006-08-24 2009-02-10 Morpholine pyrimidine derivatives useful in the treatment of proliferative disorders
IL196998A IL196998A0 (en) 2006-08-24 2009-02-11 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
ZA200901015A ZA200901015B (en) 2006-08-24 2009-02-12 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
CO09017337A CO6150160A2 (en) 2006-08-24 2009-02-20 DERIVATIVES OF MORPHOLINE PYRIMIDINE USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS
HK09108580.0A HK1130776A1 (en) 2006-08-24 2009-09-18 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0616747A GB0616747D0 (en) 2006-08-24 2006-08-24 Novel compounds

Publications (1)

Publication Number Publication Date
GB0616747D0 true GB0616747D0 (en) 2006-10-04

Family

ID=37102735

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0616747A Ceased GB0616747D0 (en) 2006-01-11 2006-08-24 Novel compounds

Country Status (7)

Country Link
CN (2) CN101541781B (en)
BR (1) BRPI0715609A2 (en)
ES (1) ES2393215T3 (en)
GB (1) GB0616747D0 (en)
RU (1) RU2440349C2 (en)
TW (1) TW200817384A (en)
ZA (1) ZA200901015B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033894T2 (en) * 2006-08-23 2018-01-29 Kudos Pharm Ltd 2-methylmorpholine pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
KR101467858B1 (en) * 2009-12-28 2014-12-02 재단법인 생물기술개발중심 NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS
US8618111B2 (en) * 2010-01-26 2013-12-31 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
CN103384672B (en) * 2011-02-25 2016-09-28 武田药品工业株式会社 The substituted piperazine of N-pteridine and piperazine pteridinone
KR20140070616A (en) * 2011-09-21 2014-06-10 셀좀 리미티드 Morpholino substituted urea or carbamate derivatives as mtor inhibitors
KR20210156333A (en) 2012-05-15 2021-12-24 캔써 리서치 테크놀로지 리미티드 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof

Also Published As

Publication number Publication date
CN101558046A (en) 2009-10-14
RU2009110255A (en) 2010-09-27
ZA200901015B (en) 2010-08-25
TW200817384A (en) 2008-04-16
RU2440349C2 (en) 2012-01-20
ES2393215T3 (en) 2012-12-19
CN101541781A (en) 2009-09-23
CN101541781B (en) 2014-01-08
BRPI0715609A2 (en) 2013-10-08

Similar Documents

Publication Publication Date Title
GB0622202D0 (en) Novel compounds
EP2034838A4 (en) Novel compounds
EP2032142A4 (en) Novel compounds
GB0603550D0 (en) Novel compounds
GB0609962D0 (en) Novel compounds
GB0616747D0 (en) Novel compounds
GB0605462D0 (en) Novel compounds
GB0602900D0 (en) Novel Compounds
GB0609117D0 (en) Novel compounds
GB0609963D0 (en) Novel compounds
EP2031965A4 (en) Novel compounds
GB0607840D0 (en) Novel compounds
GB0600483D0 (en) Novel compounds
GB0609252D0 (en) Novel sytoprotective compounds
GB0608452D0 (en) Novel compounds
GB0607892D0 (en) Novel compounds
GB0608457D0 (en) Novel compounds
GB0603897D0 (en) Novel compounds
GB0608299D0 (en) Novel Compounds
GB0607736D0 (en) Novel compounds
GB0607529D0 (en) Novel compounds
GB0607353D0 (en) Novel Compounds
GB0606763D0 (en) Novel compounds
GB0606549D0 (en) Novel compounds
GB0606527D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)